380 related articles for article (PubMed ID: 24255129)
1. A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure.
Ponikowski P; Mitrovic V; Ruda M; Fernandez A; Voors AA; Vishnevsky A; Cotter G; Milo O; Laessing U; Zhang Y; Dahlke M; Zymlinski R; Metra M
Eur Heart J; 2014 Feb; 35(7):431-41. PubMed ID: 24255129
[TBL] [Abstract][Full Text] [Related]
2. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
[TBL] [Abstract][Full Text] [Related]
3. Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study.
Teerlink JR; Voors AA; Ponikowski P; Pang PS; Greenberg BH; Filippatos G; Felker GM; Davison BA; Cotter G; Gimpelewicz C; Boer-Martins L; Wernsing M; Hua TA; Severin T; Metra M
Eur J Heart Fail; 2017 Jun; 19(6):800-809. PubMed ID: 28452195
[TBL] [Abstract][Full Text] [Related]
4. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
[TBL] [Abstract][Full Text] [Related]
5. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.
Corcoran D; Radjenovic A; Mordi IR; Nazir SA; Wilson SJ; Hinder M; Yates DP; Machineni S; Alcantara J; Prescott MF; Gugliotta B; Pang Y; Tzemos N; Semple SI; Newby DE; McCann GP; Squire I; Berry C
Cardiovasc Res; 2021 Jan; 117(1):320-329. PubMed ID: 32065620
[TBL] [Abstract][Full Text] [Related]
6. Effects of Serelaxin in Patients with Acute Heart Failure.
Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C;
N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919
[TBL] [Abstract][Full Text] [Related]
7. Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF.
Metra M; Ponikowski P; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Hua TA; Severin T; Unemori E; Voors AA; Teerlink JR
Eur Heart J; 2013 Oct; 34(40):3128-36. PubMed ID: 23999454
[TBL] [Abstract][Full Text] [Related]
8. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial.
Filippatos G; Teerlink JR; Farmakis D; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua T; Ponikowski P; Severin T; Unemori E; Voors AA; Metra M
Eur Heart J; 2014 Apr; 35(16):1041-50. PubMed ID: 24316514
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
Maggioni AP; López-Sendón J; Nielsen OW; Hallén J; Aalamian-Mattheis M; Wang Y; Ertl G
Eur J Heart Fail; 2019 Mar; 21(3):322-333. PubMed ID: 30604559
[TBL] [Abstract][Full Text] [Related]
10. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M
Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697
[TBL] [Abstract][Full Text] [Related]
11. Renal hemodynamic effects of serelaxin in patients with chronic heart failure: a randomized, placebo-controlled study.
Voors AA; Dahlke M; Meyer S; Stepinska J; Gottlieb SS; Jones A; Zhang Y; Laurent D; Slart RH; Navis GJ
Circ Heart Fail; 2014 Nov; 7(6):994-1002. PubMed ID: 25286914
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Efficacy, Safety, and Tolerability of Serelaxin When Added to Standard Therapy in Asian Patients With Acute Heart Failure: Design and Rationale of RELAX-AHF-ASIA Trial.
Sato N; Lam CS; Teerlink JR; Greenberg BH; Tsutsui H; Oh BH; Zhang J; Lefkowitz M; Hua TA; Holbro T; Marshood M; Wang XL; Ge J
J Card Fail; 2017 Jan; 23(1):63-71. PubMed ID: 27825893
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 randomised controlled trial of serelaxin to lower portal pressure in cirrhosis (STOPP).
Gifford FJ; Dunne PDJ; Weir G; Ireland H; Graham C; Tuck S; Hayes PC; Fallowfield JA
Trials; 2020 Mar; 21(1):260. PubMed ID: 32164767
[TBL] [Abstract][Full Text] [Related]
14. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
Teerlink JR; Metra M; Felker GM; Ponikowski P; Voors AA; Weatherley BD; Marmor A; Katz A; Grzybowski J; Unemori E; Teichman SL; Cotter G
Lancet; 2009 Apr; 373(9673):1429-39. PubMed ID: 19329178
[TBL] [Abstract][Full Text] [Related]
15. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.
Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M
J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour.
Weiss G; Teichman S; Stewart D; Nader D; Wood S; Breining P; Unemori E
BMC Pregnancy Childbirth; 2016 Sep; 16(1):260. PubMed ID: 27596360
[TBL] [Abstract][Full Text] [Related]
17. Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure.
Erdmann E; Semigran MJ; Nieminen MS; Gheorghiade M; Agrawal R; Mitrovic V; Mebazaa A
Eur Heart J; 2013 Jan; 34(1):57-67. PubMed ID: 22778174
[TBL] [Abstract][Full Text] [Related]
18. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.
Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M
Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514
[TBL] [Abstract][Full Text] [Related]
19. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.
Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF)
JAMA; 2002 Mar; 287(12):1531-40. PubMed ID: 11911755
[TBL] [Abstract][Full Text] [Related]
20. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial.
Marcus LS; Hart D; Packer M; Yushak M; Medina N; Danziger RS; Heitjan DF; Katz SD
Circulation; 1996 Dec; 94(12):3184-9. PubMed ID: 8989127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
